ADI News en Welsh Government adopts Dementia Action Plan <!--break--> <p><strong>15 February 2018</strong> &mdash; The Welsh Government has adopted the <a href="">Dementia Action Plan for Wales 2018-2022</a>, outlining a comprehensive response to the impact of dementia, including improving the diagnosis and support of those affected.</p> <p>Alzheimer&rsquo;s Society Cymru worked closely with the government and the <a href="">Dementia Empowerment and Engagement Project (DEEP)</a> to ensure that people affected by dementia and their care partners played a central role in the plan&#39;s development. The plan is among 32 national policies on dementia implemented worldwide. More plans are needed to provide support to 50 million people affected by dementia globally.</p> <p>&pound;10 million a year has been dedicated under the plan, in order to support people with dementia to live as independently as possible, to aid the training of healthcare professionals, and to help establish dementia friendly communities in Wales.</p> <p>Sue Phelps, at Alzheimer&#39;s Society Cymru, said,<em> &quot;The real work starts now . . . This will only work with the continued inclusion and engagement of people who live with the condition, and by building and strengthening our dementia-friendly nation, where we all play an active role and are united against dementia.&quot;</em></p> <p>Paola Barbarino, CEO of Alzheimer&#39;s Disease International, said, <em>&quot;This plan is a welcome addition to the momentum for more plans to address dementia nationally, and regionally. I am especially pleased to see the special role played by the public, and people with dementia specifically, in securing such a powerful response from the government.&quot;</em></p> <p>The plan follows the <a href="">#45000reasons</a> petition by Alzheimer Society Cymru, calling on the Welsh Assembly to develop a plan that will improve diagnosis, awareness, training for health professionals and support for people living with dementia and their care partners. It also includes a focus on improving the relationship between social care and housing, and supporting increased research on dementia. <a href="">[read more]</a></p> <h3>Where next?</h3> <ul> <li><a href="">Alzheimer&#39;s Society Cymru</a></li> <li><a href="/dementia-plans">Dementia Plans</a></li> <li><a href="/dementia-plans/global-plan">Global plan on dementia</a></li> </ul> Thu, 15 Feb 2018 11:58:41 +0000 James.Smith 3624 at Boehringer Ingelheim continues search for Alzheimer’s treatment despite trial set-back <!--break--> <p><strong>20 February 2018</strong> &ndash; <a href="">Boehringer Ingelheim</a> have shifted their attention to a new compound to treat Alzheimer&rsquo;s disease, after topline results of two Phase II trials of BI 409306 showed that it did not have efficacy when tested for Alzheimer&rsquo;s disease.</p> <p>There is hope for future success, as the company continues to search for a new treatment for Alzheimer&rsquo;s disease, the most common form of dementia. Enrolment of a Phase II trial in Alzheimer&rsquo;s Disease of a new compound, BI 425809, is planned for March and will include 600 trial participants..</p> <p>Paola Barbarino, CEO of ADI, welcomed the ongoing effort of Boehringer Ingelheim to identify new or potential treatments of dementia, following a number of high profile set-backs in recent clinical research:</p> <p><em>&ldquo;We are of course disappointed to note the results from these trials but are pleased to support the resilience and dedication with which our colleagues at Boehringer Ingelheim will continue to search for treatments that will improve the lives of people with dementia and their families globally. Investment in research is urgently needed &ndash; now is the time for industry and others to ensure we go even further to address the impact of dementia.&rdquo; </em></p> <p>Dr Jan Poth, therapeutic area head of CNS and Immunology at Boehringer Ingelheim, said, <em>&ldquo;We recognize the immense anticipation around any progress in brain research that brings us closer to finding solutions for the many millions of people living with dementia.</em></p> <p><em>However, this is what research is about . . . even these clinical trial results will add to the understanding of brain function and contribute to future progress in this area.&rdquo;</em></p> <p>Full results of the studies will be presented at the <a href="">Alzheimer&rsquo;s Association International Conference (AAIC)</a> in July in Chicago, USA. For the first time in over 17 years, the ADI Conference will be held in the same week as AAIC, offering an unparalleled opportunity to hear from the biggest global gathering of researchers in dementia understanding science, care.&nbsp; <a href="">Find out more</a>.&nbsp;</p> <h3>Where next?</h3> <ul> <li><a href="/clinical-trials">Clinical trials</a></li> <li><a href="">ADI Conference</a></li> <li><a href="/media/quick-facts">Global Impact of dementia</a></li> </ul> Tue, 20 Feb 2018 12:00:00 +0000 James.Smith 3626 at Merck remain committed after discontinuing Verubecestat study <p><strong>14 February 2018 </strong>&mdash; Pharmaceutical company Merck have announced the discontinuation of Phase III studies into the effects of Verubecestat, a possible new drug treatment for Alzheimer&rsquo;s disease.</p> <!--break--> <p>Alzheimer&rsquo;s disease is the most common form of dementia, the collective term for a range of degenerative neurological conditions that affect memory, thinking, behaviour and emotion. There is no cure for dementia and has been no new treatment for the symptoms of dementia since 2002.</p> <p>Dr Roger M. Perlmutter, President of Merck Research Laboratories, said,<em> &ldquo;We are disappointed with this outcome, especially given the lack of treatment options for patients suffering from Alzheimer&rsquo;s disease . . . despite this outcome, Merck remains committed to developing novel therapies for the treatment of Alzheimer&rsquo;s and other neurodegenerative diseases.&rdquo;</em></p> <p>Paola Barbarino, CEO of Alzheimer&rsquo;s Disease International, welcomed the continued dedication of Merck, known as MSD in Europe, to identify new and potential treatments for dementia.</p> <p>More investment is needed to support research on dementia. The <a href="/research/world-report-2016">World Alzheimer Report 2016</a> outlines key recommendations for improving health systems for dementia globally.</p> <ul> <li><a href="">Read the statement by Merck</a></li> </ul> <h3>Where next?</h3> <ul> <li><a href="/clinical-trials">Clinical trials</a></li> <li><a href="/about-dementia">About dementia</a></li> </ul> Thu, 15 Feb 2018 14:28:36 +0000 James.Smith 3625 at Wendy Weidner appointed as Research and Policy Project Lead <!--break--> <p><strong><a href=""><img alt="" height="244" src="/sites/default/files/img/Wendy_web.jpg" style="float: right; margin: 4px 20px;" width="193" /></a>06 February 2018</strong> &mdash; Wendy will join ADI on 1 March and be responsible for ADI&rsquo;s participation in the STRiDE (Strengthening responses to dementia in developing countries) project in partnership with the London School of Economics and Political Sciences (LSE) <a href="">Personal Social Services Research Unit (PSSRU)</a>, <a href="">Dementia Alliance International</a>, the <a href="">University of Sussex</a> and other universities and Alzheimer associations in seven countries.</p> <p>The STRiDE project will help to build research capacity and provide much-needed evidence on dementia care in Brazil, India, Indonesia, Jamaica, Kenya, Mexico, and South Africa. Wendy&#39;s role will also include a focus on other research that ADI is involved in, including liaising with ADI&rsquo;s Medical and Scientific Advisory Panel.</p> <p>Wendy joins ADI from <a href="">Dementia UK</a>, where her role involved working collaboratively to develop and improve dementia services, developing business cases, promoting the work of the organisation and managing the business development team. Wendy has also managed a local reminiscence project for people living with dementia and worked for a number of organisations in Africa. Wendy is American, but has been resident in the UK for many years, and also speaks French.</p> <p>Wendy said, <em>&ldquo;I&rsquo;m thrilled to be joining the ADI team and to have the opportunity to work in partnership with LSE and our member Alzheimer&rsquo;s Associations on this exciting project that will build local capacity and strengthen support for people living with dementia and their care partners.&rdquo;</em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p> <ul> <li><a href="/media/170927">Read about the STRiDE project</a></li> </ul> <p><a href=""><img alt="" src="/sites/default/files/img/GCUK-RC-logo.png" style="float: left; width: 290px; height: 110px; margin: 5px;" /></a></p> <h3>&nbsp;</h3> <h3>&nbsp;</h3> <h3>&nbsp;</h3> <h3>Where next?</h3> <ul> <li><a href="">ADI Medical and Scientific Panel&nbsp;</a></li> <li><a href="/adi-research">Global Knowledge - Research</a></li> </ul> Tue, 06 Feb 2018 10:13:49 +0000 James.Smith 3623 at Dementia included in draft WHO programme of work <!--break--> <p><strong>25 January 2018</strong> &ndash; The explicit mention of dementia has been included in the World Health Organization (WHO) <a href="">draft 13th General programme of work 2019-2023</a> following support from Member States and civil society at the 142nd Session of the WHO Executive Board in Geneva.</p> <p>Representatives of ADI attended the meeting, where a statement supported by <a href="">Dementia Alliance International (DAI)</a> expressed concern at the omission of dementia following the landmark adoption of a <a href="">Global plan on dementia</a> and the development of the WHO <a href="">Global Dementia Observatory</a> in 2017. Attention to dementia was also requested in statements made by Member State representatives from Argentina, Chile, Japan, Portugal and the UK.</p> <p>The draft programme of work outlines the priorities of the WHO for the next five-year period starting in 2019. It is expected to be approved at the meeting of the World Health Assembly, the gathering of all Member States of the WHO, in May 2018.</p> <ul> <li><a href="/sites/default/files/pdfs/Statement-%20142EB.pdf">Read the statement by ADI</a></li> </ul> <h3>Where next?</h3> <ul> <li><a href="/dementia-plans/global-plan">WHO Global plan</a></li> <li><a href="/about-dementia">About dementia</a></li> </ul> Thu, 25 Jan 2018 11:50:47 +0000 James.Smith 3622 at Statement calls for explicit inclusion of dementia in WHO work plan <!--break--> <p><strong>22 January 2018 -</strong> ADI has submitted a statement to the 142nd Session of the World Health Organization (WHO) Executive Board, calling for the urgent inclusion of dementia in the <a href=""><em>13th WHO General programme of work 2019-2023</em></a><em>.</em></p> <p>Representatives of ADI are in attendance at the meeting of the Board, where the current draft of the programme of work will be considered by 34 WHO Member States. The statement in partnership with <a href="">Dementia Alliance International</a> outlines the importance of the specific&nbsp;inclusion of dementia to retain global and national momentum to prioritise the disease.</p> <p>Paola Barbarino, CEO of ADI, is expected to say that, <em>&quot;</em><em>We strongly feel that mentioning dementia in the programme of work is key to the success of global advocacy for change. Civil society needs to be empowered to persuade the world that dementia cannot be hidden.&quot;</em></p> <p>Dementia has gained important recognition by the WHO following the adoption of the <a href=""><em>Global plan of action on the public health response to dementia 2017-2025</em></a><em>,</em> and development of the <a href="">Global Dementia Observatory</a> in 2017. By giving dementia formal visibility in its work plan, it is hoped that all&nbsp;countries may continue to progress national policies to advance the awareness, prevention and diagnosis, treatment, research and care of, and for those affected.</p> <ul> <li><a href="/sites/default/files/pdfs/Statement-%20142EB.pdf">Read the full statement</a></li> </ul> <h3>Where next?&nbsp;</h3> <ul> <li><a href="/dementia-plans/global-plan">Global plan on dementia</a></li> <li><a href="/about-dementia">About dementia</a></li> </ul> Mon, 22 Jan 2018 10:00:00 +0000 James.Smith 3621 at ADI recruiting for Membership Manager <p><strong>10 January 2018</strong> - ADI is looking for an experienced individual to support the work and development of existing and new members around the world. <a href="/jobs">[read more]</a></p> Wed, 10 Jan 2018 16:43:38 +0000 James.Smith 3620 at Registration for ADI2018 is now open <!--break--> <p><a href=""><img alt="" src="/sites/default/files/img/Chicago-Banner-960px-2.jpg" style="width: 640px; height: 307px;" /></a></p> <p><strong>04 January 2017</strong>&nbsp;&ndash; Registration for ADI2018 is now open. The conference will feature global experts on a range of topics including the latest in dementia science and care, presentations by people with dementia and their care partners and&nbsp;a unique focus on how technology and innovation is shaping the future.</p> <p>Early-bird registration closes <strong>30 April 2018.</strong></p> <p>Visit the <a href="">registration page</a> for more information.</p> Fri, 05 Jan 2018 09:07:45 +0000 James.Smith 3619 at Global Perspective Newsletter for December 2017 <p><a href="/sites/default/files/pdfs/GP-December-2017_0.pdf"><img alt="" src="/sites/default/files/pdfs/GP-December-2017.png" style="float: left; width: 80px; height: 114px; margin: 5px 10px;" /></a> The December 2017 issue of our<em> Global Perspective</em> newsletter is now available. This issue includes news from World Alzheimer&#39;s Month 2017, ADI meetings and regular features and contributions from Alzheimer associations and our partners. <a href="/sites/default/files/pdfs/GP-December-2017.pdf">[Read it now]</a></p> Tue, 19 Dec 2017 09:00:00 +0000 James.Smith 3618 at Bob and Diane Fund award dementia photography <p><strong>11 December 2017</strong> - The <a href="">Bob and Diane Fund</a> have awarded USD $5,000 to Christopher Nunn, in recognition of his photography project depicting the early stages of Alzheimer&rsquo;s Disease.</p> <!--break--> <p>The Fund was launched by Gina Martin in 2016, named after her mother who lived with dementia and her father who was her primary caregiver. The grant from the fund emphasizes the role that images can play in raising awareness of dementia, supporting artists who capture the experience of the disease with dignity and respect.</p> <p>Dementia affects 50 million people around the world. The stigma that surrounds dementias, including Alzheimer&rsquo;s disease, remains a global problem.</p> <p>Gina said, <em>&ldquo;Visual stories of patients and caregivers can humanize what is, in fact, a very cruel and dehumanizing disease. My hope is that the work funded today and in the future will have a profound and lasting effect on people, persuading them to support and advocate for a cure.&rdquo;</em></p> <p>Christopher Nunn is a British photographer whose work, <a href=""><em>&lsquo;Falling into the Day&rsquo;</em></a>, illustrates the journey of his neighbor in the early stages of Alzheimer&rsquo;s disease and was chosen from over 60 submissions from 22 countries.</p> <h3>Where next?</h3> <ul> <li><a href="/about-dementia">About dementia </a></li> <li><a href="">About ADI</a></li> </ul> Mon, 11 Dec 2017 12:25:44 +0000 James.Smith 3610 at